Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02798406
Title Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors DNAtrix, Inc.
Indications

gliosarcoma

glioblastoma

Therapies

DNX-2401 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.